Robeco Institutional Asset Management B.V. Buys Shares of 197,554 Cellebrite DI Ltd. (NASDAQ:CLBT)

Robeco Institutional Asset Management B.V. bought a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 197,554 shares of the company's stock, valued at approximately $3,838,000. Robeco Institutional Asset Management B.V. owned approximately 0.08% of Cellebrite DI at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Axon Enterprise Inc. bought a new position in Cellebrite DI during the fourth quarter valued at $198,270,000. FMR LLC boosted its stake in shares of Cellebrite DI by 89.1% during the 4th quarter. FMR LLC now owns 10,621,344 shares of the company's stock worth $233,988,000 after purchasing an additional 5,004,587 shares during the period. Invesco Ltd. bought a new position in Cellebrite DI during the 4th quarter valued at about $32,700,000. Handelsbanken Fonder AB grew its holdings in Cellebrite DI by 749.9% during the 1st quarter. Handelsbanken Fonder AB now owns 1,518,700 shares of the company's stock valued at $29,508,000 after purchasing an additional 1,340,000 shares during the last quarter. Finally, AQR Capital Management LLC purchased a new stake in Cellebrite DI in the 4th quarter worth about $16,205,000. Hedge funds and other institutional investors own 45.88% of the company's stock.

Analyst Upgrades and Downgrades

CLBT has been the subject of several recent analyst reports. JPMorgan Chase & Co. dropped their target price on Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research report on Monday, May 12th. Needham & Company LLC restated a "buy" rating and set a $24.00 price objective on shares of Cellebrite DI in a report on Friday, June 6th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Cellebrite DI has an average rating of "Buy" and a consensus price target of $22.43.

Cellebrite DI Price Performance

Shares of CLBT stock traded up $0.12 during mid-day trading on Friday, hitting $15.32. The stock had a trading volume of 1,149,826 shares, compared to its average volume of 1,478,497. Cellebrite DI Ltd. has a 12-month low of $11.47 and a 12-month high of $26.30. The firm's 50-day moving average is $17.29 and its two-hundred day moving average is $19.52. The firm has a market capitalization of $3.67 billion, a P/E ratio of -15.95, a price-to-earnings-growth ratio of 3.12 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.01. Cellebrite DI had a positive return on equity of 35.36% and a negative net margin of 46.34%. The firm had revenue of $107.55 million during the quarter, compared to the consensus estimate of $109.36 million. During the same period in the previous year, the company posted $0.08 earnings per share. The firm's quarterly revenue was up 20.0% on a year-over-year basis. Analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.